Global Companion Diagnostics Market anticipated reaching USD 18 Billion by 2035
An extensive study of propelling opportunities in, “Companion Diagnostics Market Size, Share & Trends Analysis Report by Product & Service (Assay Kits & Reagents, Software & Services), by Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Others (e.g., gene chips, flow cytometry)), Indication, Cancer Type (within Oncology), Sample Type, Mode of Testing, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive report of growing market landscapes in the companion diagnostics sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting companion diagnostics potential to scale globally.
Global Companion Diagnostics Market Forecast 2035:
According to the report, the companion diagnostics market is anticipated to grow from USD 7 Billion in 2025 to USD 18 Billion in 2035 at a CAGR of 9.9% during the forecast. The companion diagnostics (CDx) industry is changing rapidly. Due to the implementation of precision medicine and targeted therapies in oncology and rare diseases, numerous new business opportunities are probable. Advances in genomics and next-generation sequencing (NGS) technologies have potential for better, more precise therapeutic actions as the pharmaceutical industry begins to favor biomarker-led decisions in treatment from regulators and payers alike.
Further, pharma companies likely to increasingly enter into strategic partnerships with diagnostic companies in North America and Western Europe. There are also pilot studies emerging in China and the UAE that are testing population-scale genomic screening platforms mapped to national databases, which inform early stages of developing CDx for modifiers in treatment pathways.
The CDx market is seemingly plagued by challenges like misalignment of regulatory pathways for drugs and diagnostics, access to testing and infrastructure, and reimbursement. Furthermore, cross-border governance for data and interoperability between multi-vendor diagnostic mechanisms are a challenge. The sophistication of the developing landscape includes multi-analyte diagnostics and performance-enhanced diagnostics through AI/ML development and evaluation.
Thus, it is likely to be important for stakeholders on the same page regarding clinical validation and real-world experience uptake needed for the broader global uptake in XRAY protocols.
“Key Driver, Restraint, and Growth Opportunity Defining the Global Companion Diagnostics Market”
Personalized medicine, particularly in oncology, is the central thrust of the companion diagnostics market, where biomarker identification is an integral factor in treatment efficacy. The increasing utilization of next-generation sequencing (NGS) and targeted therapies necessitates the use of accurate diagnostic tools to stratify patient populations to improve treatment outcomes and limit unnecessary exposure to drugs.
A key restraint factors is that there is no harmonized requirements for regulatory pathways between therapeutics and diagnostics. This can adversely affect the co-approval and market access of drugs and diagnostic tools for the same indications. The high costs and the validation requirements of development may also discourage smaller companies. Also, there are restrictions stemming from variability in test availability and lack of reimbursement for diagnostic procedural tests can dissuade adoption in some instances across different clinical settings and low resources settings.
There is potential for growth from the expansion of multi-gene panel testing and liquid biopsy technologies as these testing approaches are often viewed as less invasive and allow for quicker diagnostic turnaround time. Collaboration between pharmaceutical companies and diagnostics companies are resulting in strategic partnerships allowing co-development models that provide expedited market access. In addition, there are supportive government initiatives focused on precision medicine and genomic research that provide a solid springboard for increased implementation of CDx in the management of chronic and rare diseases.
"Impact of Global Tariff Policies on the Global Companion Diagnostics Market Growth and Strategy"
Global tariff policies have a complex and indirect effect on the Companion Diagnostics (CDx) market. Many CDx platforms involve cross-border shipments of highly specialized reagents, instruments, and molecular testing material, most of which are imported from the U.S., EU, or East Asia, and tariffs associated with diagnostic devices or raw materials can increase the cost of goods sold (COGS), particularly in developing regions where a local manufacturing capacity does not exist.
Higher end-user pricing is incurred on the back end which ultimately drives up the access to the tests themselves for even the most basic core value of care delivery in emerging healthcare systems. If access to the tests is restricted due to increased costs as a direct impact of tariff increases, then it can be reasonably assumed that CDx developers may modify their strategy to incorporate more localized manufacturing or even develop regional partnerships in order to produce solutions that mitigate tariff exposure.
Furthermore, tariff exposures are referred to as geopolitical risk exposures, and global pharmaceutical and diagnostic associations are considering geopolitical risk much more extensively than in the past, particularly as they look to diversify supply chains and incorporate a more modular, distributed manufacturing strategy to insulate themselves from the impact of tariffs.
Expansion of Global Companion Diagnostics Market
"Precision Medicine, Biomarker Discovery, and Pharma-Diagnostics Alliances Drive Companion Diagnostics Acceleration"
- The companion diagnostics market is exhibiting considerable growth due to the increasing use of precision medicine, where interventions are made on a case-by-case basis (the lawyer's motto in drug development that is becoming a healthcare motto), based on genes or other parameters related to a patient or disease. This is facilitated by biomarker discovery that helps clinicians choose the right drug for the right patient.
- Moreover, there are also many more partnerships between pharmaceutical companies and diagnostic developers. These partnerships help ensure that all new drugs have tests that will help identify the patients that may benefit the most. Collectively, these trends will generate a more effective and safer treatment paradigm, which is generating increased demand for companion diagnostics across the world.
Regional Analysis of Companion Diagnostics Market
- North America occupies the lead position in the companion diagnostics market, primarily guided by a lot of investments made to advance precision medicine, robust workflows associated with built environment for healthcare, and early adoption of newer technologies. The U.S. pharmaceutical and diagnostic companies benefit from favorable regulatory environments and mutual collaborations.
- Furthermore, Europe is also growing, in part due to government initiatives promoting personalized healthcare. The Asia-Pacific region, particularly China and Japan, is an emerging region growing rapidly due to increasing cancer rates, evidence of genomic studies, and expanding access improved multi-platform usage of molecular diagnostics. However, challenges do exist in lower-income countries because of access to testing or affordability.
Key players in the global companion diagnostics market include prominent companies such as Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Almac Group, ArcherDX (a part of Invitae), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Exact Sciences Corporation, Foundation Medicine, Inc., Guardant Health, Inc., Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., Qiagen N.V., Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., ThermoGenesis Holdings, Inc., and other key players along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.
The Companion Diagnostics Market has been segmented as follows:
Companion Diagnostics Market Analysis, by Product & Service
- Assay Kits & Reagents
- Software & Services
Companion Diagnostics Market Analysis, by Technology
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Others (e.g., gene chips, flow cytometry)
Companion Diagnostics Market Analysis, by Indication
- Oncology
- Neurology
- Infectious Diseases
- Cardiovascular Diseases
- Others
Companion Diagnostics Market Analysis, by Cancer Type (within Oncology)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Cancer Types
Companion Diagnostics Market Analysis, by Sample Type
- Blood
- Tissue Biopsies
- Saliva
- Others
Companion Diagnostics Market Analysis, by Mode of Testing
- Laboratory-Based
- Point-of-Care
Companion Diagnostics Market Analysis, by End User
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- Contract Research Organizations
- Hospitals & Specialty Clinics
- Others
Companion Diagnostics Market Analysis, by Region
- North America
- Europe
- Asia Pacific
- Middle East
- Africa
- South America
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact US
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Companion Diagnostics Market Outlook
- 2.1.1. Global Companion Diagnostics Market Size (Value - USD Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Companion Diagnostics Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Companion Diagnostics Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.6. Raw Material Analysis
- 3.1. Companion Diagnostics Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Surge in Personalized Medicine and Biomarker-Driven Targeted Therapies
- 4.1.2. Restraints
- 4.1.2.1. High Development Costs and Complex Regulatory Landscape Restrict Market Growth
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.4.1. Raw Components Sourcing
- 4.4.2. Manufacturing and Processing
- 4.4.3. Wholesalers/ E-commerce Platform
- 4.4.4. End-use/ Customers
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Companion Diagnostics Market Demand
- 4.9.1. Historical Market Size - Value (Value - USD Bn), 2021-2024
- 4.9.2. Current and Future Market Size - Value (Value - USD Bn), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Companion Diagnostics Market Analysis, by Product & Service
- 6.1. Key Segment Analysis
- 6.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Product & Service, 2021-2035
- 6.2.1. Assay Kits & Reagents
- 6.2.2. Software & Services
- 7. Global Companion Diagnostics Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Polymerase Chain Reaction (PCR)
- 7.2.2. In Situ Hybridization (ISH)
- 7.2.3. Immunohistochemistry (IHC)
- 7.2.4. Next-Generation Sequencing (NGS)
- 7.2.5. Others (e.g., gene chips, flow cytometry)
- 8. Global Companion Diagnostics Market Analysis, by Indication
- 8.1. Key Segment Analysis
- 8.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Indication, 2021-2035
- 8.2.1. Oncology
- 8.2.2. Neurology
- 8.2.3. Infectious Diseases
- 8.2.4. Cardiovascular Diseases
- 8.2.5. Others
- 9. Global Companion Diagnostics Market Analysis, by Cancer Type (within Oncology)
- 9.1. Key Segment Analysis
- 9.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Cancer Type (within Oncology), 2021-2035
- 9.2.1. Breast Cancer
- 9.2.2. Lung Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Prostate Cancer
- 9.2.5. Other Cancer Types
- 10. Global Companion Diagnostics Market Analysis, by Sample Type
- 10.1. Key Segment Analysis
- 10.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Sample Type, 2021-2035
- 10.2.1. Blood
- 10.2.2. Tissue Biopsies
- 10.2.3. Saliva
- 10.2.4. Others
- 11. Global Companion Diagnostics Market Analysis, by Mode of Testing
- 11.1. Key Segment Analysis
- 11.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Mode of Testing, 2021-2035
- 11.2.1. Laboratory-Based
- 11.2.2. Point-of-Care
- 12. Global Companion Diagnostics Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by End User, 2021-2035
- 12.2.1. Pharmaceutical & Biopharmaceutical Companies
- 12.2.2. Reference Laboratories
- 12.2.3. Contract Research Organizations
- 12.2.4. Hospitals & Specialty Clinics
- 12.2.5. Others
- 13. Global Companion Diagnostics Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Global Companion Diagnostics Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Product & Service
- 14.3.2. Technology
- 14.3.3. Indication
- 14.3.4. Cancer Type
- 14.3.5. Sample Type
- 14.3.6. Mode of Testing
- 14.3.7. Mode of Operation
- 14.3.8. End User
- 14.3.9. Country
- 14.3.9.1. USA
- 14.3.9.2. Canada
- 14.3.9.3. Mexico
- 14.4. USA Global Companion Diagnostics Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Product & Service
- 14.4.3. Technology
- 14.4.4. Indication
- 14.4.5. Cancer Type
- 14.4.6. Sample Type
- 14.4.7. Mode of Testing
- 14.4.8. Mode of Operation
- 14.4.9. End User
- 14.5. Canada Global Companion Diagnostics Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Product & Service
- 14.5.3. Technology
- 14.5.4. Indication
- 14.5.5. Cancer Type
- 14.5.6. Sample Type
- 14.5.7. Mode of Testing
- 14.5.8. Mode of Operation
- 14.5.9. End User
- 14.6. Mexico Global Companion Diagnostics Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Product & Service
- 14.6.3. Technology
- 14.6.4. Indication
- 14.6.5. Cancer Type
- 14.6.6. Sample Type
- 14.6.7. Mode of Testing
- 14.6.8. Mode of Operation
- 14.6.9. End User
- 15. Europe Global Companion Diagnostics Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Product & Service
- 15.3.2. Technology
- 15.3.3. Indication
- 15.3.4. Cancer Type
- 15.3.5. Sample Type
- 15.3.6. Mode of Testing
- 15.3.7. Mode of Operation
- 15.3.8. End User
- 15.3.9. Country
- 15.3.9.1. Germany
- 15.3.9.2. United Kingdom
- 15.3.9.3. France
- 15.3.9.4. Italy
- 15.3.9.5. Spain
- 15.3.9.6. Netherlands
- 15.3.9.7. Nordic Countries
- 15.3.9.8. Poland
- 15.3.9.9. Russia & CIS
- 15.3.9.10. Rest of Europe
- 15.4. Germany Global Companion Diagnostics Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Product & Service
- 15.4.3. Technology
- 15.4.4. Indication
- 15.4.5. Cancer Type
- 15.4.6. Sample Type
- 15.4.7. Mode of Testing
- 15.4.8. Mode of Operation
- 15.4.9. End User
- 15.5. United Kingdom Global Companion Diagnostics Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Product & Service
- 15.5.3. Technology
- 15.5.4. Indication
- 15.5.5. Cancer Type
- 15.5.6. Sample Type
- 15.5.7. Mode of Testing
- 15.5.8. Mode of Operation
- 15.5.9. End User
- 15.6. France Global Companion Diagnostics Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Product & Service
- 15.6.3. Technology
- 15.6.4. Indication
- 15.6.5. Cancer Type
- 15.6.6. Sample Type
- 15.6.7. Mode of Testing
- 15.6.8. Mode of Operation
- 15.6.9. End User
- 15.7. Italy Global Companion Diagnostics Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Product & Service
- 15.7.3. Technology
- 15.7.4. Indication
- 15.7.5. Cancer Type
- 15.7.6. Sample Type
- 15.7.7. Mode of Testing
- 15.7.8. Mode of Operation
- 15.7.9. End User
- 15.8. Spain Global Companion Diagnostics Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Product & Service
- 15.8.3. Technology
- 15.8.4. Indication
- 15.8.5. Cancer Type
- 15.8.6. Sample Type
- 15.8.7. Mode of Testing
- 15.8.8. Mode of Operation
- 15.8.9. End User
- 15.9. Netherlands Global Companion Diagnostics Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Product & Service
- 15.9.3. Technology
- 15.9.4. Indication
- 15.9.5. Cancer Type
- 15.9.6. Sample Type
- 15.9.7. Mode of Testing
- 15.9.8. Mode of Operation
- 15.9.9. End User
- 15.10. Nordic Countries Global Companion Diagnostics Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Product & Service
- 15.10.3. Technology
- 15.10.4. Indication
- 15.10.5. Cancer Type
- 15.10.6. Sample Type
- 15.10.7. Mode of Testing
- 15.10.8. Mode of Operation
- 15.10.9. End User
- 15.11. Poland Global Companion Diagnostics Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Product & Service
- 15.11.3. Technology
- 15.11.4. Indication
- 15.11.5. Cancer Type
- 15.11.6. Sample Type
- 15.11.7. Mode of Testing
- 15.11.8. Mode of Operation
- 15.11.9. End User
- 15.12. Russia & CIS Global Companion Diagnostics Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Product & Service
- 15.12.3. Technology
- 15.12.4. Indication
- 15.12.5. Cancer Type
- 15.12.6. Sample Type
- 15.12.7. Mode of Testing
- 15.12.8. Mode of Operation
- 15.12.9. End User
- 15.13. Rest of Europe Global Companion Diagnostics Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Product & Service
- 15.13.3. Technology
- 15.13.4. Indication
- 15.13.5. Cancer Type
- 15.13.6. Sample Type
- 15.13.7. Mode of Testing
- 15.13.8. Mode of Operation
- 15.13.9. End User
- 16. Asia Pacific Global Companion Diagnostics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Product & Service
- 16.3.2. Technology
- 16.3.3. Indication
- 16.3.4. Cancer Type
- 16.3.5. Sample Type
- 16.3.6. Mode of Testing
- 16.3.7. Mode of Operation
- 16.3.8. End User
- 16.3.9. Country
- 16.3.9.1. China
- 16.3.9.2. India
- 16.3.9.3. Japan
- 16.3.9.4. South Korea
- 16.3.9.5. Australia and New Zealand
- 16.3.9.6. Indonesia
- 16.3.9.7. Malaysia
- 16.3.9.8. Thailand
- 16.3.9.9. Vietnam
- 16.3.9.10. Rest of Asia-Pacific
- 16.4. China Global Companion Diagnostics Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Product & Service
- 16.4.3. Technology
- 16.4.4. Indication
- 16.4.5. Cancer Type
- 16.4.6. Sample Type
- 16.4.7. Mode of Testing
- 16.4.8. Mode of Operation
- 16.4.9. End User
- 16.5. India Global Companion Diagnostics Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Product & Service
- 16.5.3. Technology
- 16.5.4. Indication
- 16.5.5. Cancer Type
- 16.5.6. Sample Type
- 16.5.7. Mode of Testing
- 16.5.8. Mode of Operation
- 16.5.9. End User
- 16.6. Japan Global Companion Diagnostics Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Product & Service
- 16.6.3. Technology
- 16.6.4. Indication
- 16.6.5. Cancer Type
- 16.6.6. Sample Type
- 16.6.7. Mode of Testing
- 16.6.8. Mode of Operation
- 16.6.9. End User
- 16.7. South Korea Global Companion Diagnostics Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Product & Service
- 16.7.3. Technology
- 16.7.4. Indication
- 16.7.5. Cancer Type
- 16.7.6. Sample Type
- 16.7.7. Mode of Testing
- 16.7.8. Mode of Operation
- 16.7.9. End User
- 16.8. Australia and New Zealand Global Companion Diagnostics Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Product & Service
- 16.8.3. Technology
- 16.8.4. Indication
- 16.8.5. Cancer Type
- 16.8.6. Sample Type
- 16.8.7. Mode of Testing
- 16.8.8. Mode of Operation
- 16.8.9. End User
- 16.9. Indonesia Global Companion Diagnostics Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Product & Service
- 16.9.3. Technology
- 16.9.4. Indication
- 16.9.5. Cancer Type
- 16.9.6. Sample Type
- 16.9.7. Mode of Testing
- 16.9.8. Mode of Operation
- 16.9.9. End User
- 16.10. Malaysia Global Companion Diagnostics Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Product & Service
- 16.10.3. Technology
- 16.10.4. Indication
- 16.10.5. Cancer Type
- 16.10.6. Sample Type
- 16.10.7. Mode of Testing
- 16.10.8. Mode of Operation
- 16.10.9. End User
- 16.11. Thailand Global Companion Diagnostics Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Product & Service
- 16.11.3. Technology
- 16.11.4. Indication
- 16.11.5. Cancer Type
- 16.11.6. Sample Type
- 16.11.7. Mode of Testing
- 16.11.8. Mode of Operation
- 16.11.9. End User
- 16.12. Vietnam Global Companion Diagnostics Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Product & Service
- 16.12.3. Technology
- 16.12.4. Indication
- 16.12.5. Cancer Type
- 16.12.6. Sample Type
- 16.12.7. Mode of Testing
- 16.12.8. Mode of Operation
- 16.12.9. End User
- 16.13. Rest of Asia Pacific Global Companion Diagnostics Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Product & Service
- 16.13.3. Technology
- 16.13.4. Indication
- 16.13.5. Cancer Type
- 16.13.6. Sample Type
- 16.13.7. Mode of Testing
- 16.13.8. Mode of Operation
- 16.13.9. End User
- 17. Middle East Global Companion Diagnostics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Product & Service
- 17.3.2. Technology
- 17.3.3. Indication
- 17.3.4. Cancer Type
- 17.3.5. Sample Type
- 17.3.6. Mode of Testing
- 17.3.7. Mode of Operation
- 17.3.8. End User
- 17.3.9. Country
- 17.3.9.1. Turkey
- 17.3.9.2. UAE
- 17.3.9.3. Saudi Arabia
- 17.3.9.4. Israel
- 17.3.9.5. Rest of Middle East
- 17.4. Turkey Global Companion Diagnostics Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Product & Service
- 17.4.3. Technology
- 17.4.4. Indication
- 17.4.5. Cancer Type
- 17.4.6. Sample Type
- 17.4.7. Mode of Testing
- 17.4.8. Mode of Operation
- 17.4.9. End User
- 17.5. UAE Global Companion Diagnostics Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Product & Service
- 17.5.3. Technology
- 17.5.4. Indication
- 17.5.5. Cancer Type
- 17.5.6. Sample Type
- 17.5.7. Mode of Testing
- 17.5.8. Mode of Operation
- 17.5.9. End User
- 17.6. Saudi Arabia Global Companion Diagnostics Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Product & Service
- 17.6.3. Technology
- 17.6.4. Indication
- 17.6.5. Cancer Type
- 17.6.6. Sample Type
- 17.6.7. Mode of Testing
- 17.6.8. Mode of Operation
- 17.6.9. End User
- 17.7. Israel Global Companion Diagnostics Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Product & Service
- 17.7.3. Technology
- 17.7.4. Indication
- 17.7.5. Cancer Type
- 17.7.6. Sample Type
- 17.7.7. Mode of Testing
- 17.7.8. Mode of Operation
- 17.7.9. End User
- 17.8. Rest of Middle East Global Companion Diagnostics Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Product & Service
- 17.8.3. Technology
- 17.8.4. Indication
- 17.8.5. Cancer Type
- 17.8.6. Sample Type
- 17.8.7. Mode of Testing
- 17.8.8. Mode of Operation
- 17.8.9. End User
- 18. Africa Global Companion Diagnostics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Product & Service
- 18.3.2. Technology
- 18.3.3. Indication
- 18.3.4. Cancer Type
- 18.3.5. Sample Type
- 18.3.6. Mode of Testing
- 18.3.7. Mode of Operation
- 18.3.8. End User
- 18.3.9. Country
- 18.3.9.1. South Africa
- 18.3.9.2. Egypt
- 18.3.9.3. Nigeria
- 18.3.9.4. Algeria
- 18.3.9.5. Rest of Africa
- 18.4. South Africa Global Companion Diagnostics Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Product & Service
- 18.4.3. Technology
- 18.4.4. Indication
- 18.4.5. Cancer Type
- 18.4.6. Sample Type
- 18.4.7. Mode of Testing
- 18.4.8. Mode of Operation
- 18.4.9. End User
- 18.5. Egypt Global Companion Diagnostics Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Product & Service
- 18.5.3. Technology
- 18.5.4. Indication
- 18.5.5. Cancer Type
- 18.5.6. Sample Type
- 18.5.7. Mode of Testing
- 18.5.8. Mode of Operation
- 18.5.9. End User
- 18.6. Nigeria Global Companion Diagnostics Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Product & Service
- 18.6.3. Technology
- 18.6.4. Indication
- 18.6.5. Cancer Type
- 18.6.6. Sample Type
- 18.6.7. Mode of Testing
- 18.6.8. Mode of Operation
- 18.6.9. End User
- 18.7. Algeria Global Companion Diagnostics Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Product & Service
- 18.7.3. Technology
- 18.7.4. Indication
- 18.7.5. Cancer Type
- 18.7.6. Sample Type
- 18.7.7. Mode of Testing
- 18.7.8. Mode of Operation
- 18.7.9. End User
- 18.8. Rest of Africa Global Companion Diagnostics Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Product & Service
- 18.8.3. Technology
- 18.8.4. Indication
- 18.8.5. Cancer Type
- 18.8.6. Sample Type
- 18.8.7. Mode of Testing
- 18.8.8. Mode of Operation
- 18.8.9. End User
- 19. South America Global Companion Diagnostics Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Product & Service
- 19.3.2. Technology
- 19.3.3. Indication
- 19.3.4. Cancer Type
- 19.3.5. Sample Type
- 19.3.6. Mode of Testing
- 19.3.7. Mode of Operation
- 19.3.8. End User
- 19.3.9. Country
- 19.3.9.1. Brazil
- 19.3.9.2. Argentina
- 19.3.9.3. Rest of South America
- 19.4. Brazil Global Companion Diagnostics Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Product & Service
- 19.4.3. Technology
- 19.4.4. Indication
- 19.4.5. Cancer Type
- 19.4.6. Sample Type
- 19.4.7. Mode of Testing
- 19.4.8. Mode of Operation
- 19.4.9. End User
- 19.5. Argentina Global Companion Diagnostics Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Product & Service
- 19.5.3. Technology
- 19.5.4. Indication
- 19.5.5. Cancer Type
- 19.5.6. Sample Type
- 19.5.7. Mode of Testing
- 19.5.8. Mode of Operation
- 19.5.9. End User
- 19.6. Rest of South America Global Companion Diagnostics Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Product & Service
- 19.6.3. Technology
- 19.6.4. Indication
- 19.6.5. Cancer Type
- 19.6.6. Sample Type
- 19.6.7. Mode of Testing
- 19.6.8. Mode of Operation
- 19.6.9. End User
- 20. Key Players/ Company Profile
- 20.1. Abbott Laboratories
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Adaptive Biotechnologies
- 20.3. Agilent Technologies, Inc.
- 20.4. Almac Group
- 20.5. ArcherDX (a part of Invitae)
- 20.6. bioMérieux SA
- 20.7. Bio-Rad Laboratories, Inc.
- 20.8. Danaher Corporation
- 20.9. Exact Sciences Corporation
- 20.10. Foundation Medicine, Inc.
- 20.11. Guardant Health, Inc.
- 20.12. Illumina, Inc.
- 20.13. Invitae Corporation
- 20.14. Myriad Genetics, Inc.
- 20.15. Qiagen N.V.
- 20.16. Roche Diagnostics
- 20.17. Siemens Healthineers
- 20.18. Sysmex Corporation
- 20.19. Thermo Fisher Scientific Inc.
- 20.20. ThermoGenesis Holdings, Inc.
- 20.21. Other key Players
- 20.1. Abbott Laboratories
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
